Peel Therapeutics
PrivateLast Round
Grant
Feb 23, 2023
Total Funding Raised
$39M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Peel Therapeutics is a biotechnology company that develops anti-cancer protein nanoparticles aimed at treating cancer by regulating cellular responses to environmental stresses.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Infrastructure
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Peel Therapeutics Comparables
Compare Peel Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Gibson Oncology, LLC | 80% | |
| Eris Biotech | 71% | |
| Sirenas Marine Discovery | 66% | |
Peel Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Feb 23, 2023 | ||||
| Seed | Feb 23, 2023 | ||||
| Seed | Aug 10, 2022 |
Peel Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| NIH RADx | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors increased 35% MoM.
Peel Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |